- Home
- CLGN vs SONN Comparison
CLGN vs SONN Comparison
Compare CLGN & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- SONN
- Stock Information
- Founded
- CLGN 2004
- SONN N/A
- Country
- CLGN Israel
- SONN United States
- Employees
- CLGN N/A
- SONN N/A
- Industry
- CLGN Industrial Specialties
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- CLGN Health Care
- SONN Health Care
- Exchange
- CLGN Nasdaq
- SONN Nasdaq
- Market Cap
- CLGN 33.8M
- SONN 32.4M
- IPO Year
- CLGN N/A
- SONN N/A
- Fundamental
- Price
- CLGN $2.07
- SONN $4.23
- Analyst Decision
- CLGN Strong Buy
- SONN Strong Buy
- Analyst Count
- CLGN 2
- SONN 1
- Target Price
- CLGN $11.50
- SONN $20.00
- AVG Volume (30 Days)
- CLGN 34.5K
- SONN 583.1K
- Earning Date
- CLGN 11-26-2025
- SONN 12-16-2025
- Dividend Yield
- CLGN N/A
- SONN N/A
- EPS Growth
- CLGN N/A
- SONN N/A
- EPS
- CLGN N/A
- SONN N/A
- Revenue
- CLGN $2,402,000.00
- SONN $1,000,000.00
- Revenue This Year
- CLGN $1,617.28
- SONN $5,376.22
- Revenue Next Year
- CLGN $83.54
- SONN N/A
- P/E Ratio
- CLGN N/A
- SONN N/A
- Revenue Growth
- CLGN 248.62
- SONN 1689.52
- 52 Week Low
- CLGN $1.31
- SONN $1.08
- 52 Week High
- CLGN $4.98
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- CLGN 37.05
- SONN 47.78
- Support Level
- CLGN $2.12
- SONN $3.12
- Resistance Level
- CLGN $2.27
- SONN $4.72
- Average True Range (ATR)
- CLGN 0.13
- SONN 0.71
- MACD
- CLGN -0.01
- SONN -0.03
- Stochastic Oscillator
- CLGN 0.00
- SONN 40.64
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.